Novo Nordisk announced headline results from the REIMAGINE 2 (NCT06065540) phase 3 trial, revealing that its experimental therapy, CagriSema, achieved statistically significant superiority in both blood glucose control and weight…
The management of diabetes in specialized populations, particularly children and pregnant women, is entering a new era as inhaled Technosphere insulin (TI) emerges as a potential solution to long-standing therapeutic…
Diabetes remission is defined as maintaining a hemoglobin A1c (HbA1c) level of less than 6.5% for at least 3 months without the use of glucose-lowering medications. Although traditional type 2…
Recent findings from a 12-week prospective study have illuminated the potential of high-dose vitamin D3 as a strategic tool for managing metabolic health in patients with type 2 diabetes (T2D).…